Biotech News
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL
New York, NY - October 16, 2025 - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today hosts a R&D Day in New York City. The Company's leadership team and key opinion leaders will present the full Phase 1 dataset and outline the pivotal Phase 2 trial design and commercial opportunity for lasme-cel in r/r B-ALL.
Details of the Event:
Date: Today, October 16, 2025
Time: 08:30 - 10:30 a.m. ET
Format: In-person and live webcast
Webcast: Join live via https://us06web.zoom.us/j/84630848404
A replay will be available after the event on the Cellectis website